Skip to main content
Caplight Logo









Nanopath

Nanopath

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://nanopath.com/

Last Round

Grant

May 21, 2024

Total Funding Raised

$14M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Nanopath is a diagnostic equipment company that has developed a molecular diagnostic platform designed to enable point-of-care disease diagnosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Sensors

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

molecular diagnosticspoint-of-care testingPOCTpathogen detectionnanosensor technologyamplification-free diagnosticslab-on-a-chipdiagnostic cartridgesrapid diagnosticswomen's health diagnosticsclinical diagnosticsbiosensorrazor-and-blades modelmedical device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanopath Comparables

Compare Nanopath with similar companies based on industry and business-model similarity.

Nanopath comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rover Diagnostics
85%
AltraTech Limited
78%
GRIP Molecular Technologies
78%

Nanopath Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 21, 2024
Series AAug 9, 2022

Key People

Founding team and executive leadership

Alison Burklund

Co-Founder & Co-CEO

Founding Team

Amogha Tadimety

Co-Founder & Co-CEO

Founding Team

Nanopath Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Open roles increased to 45, 3x the trailing average.

  • Jul 13, 2026

    Open roles increased to 13, 42% of headcount.

Recent news

Latest coverage and updates

  • is_developingSep 26, 2026

    Nanopath Inc. is developing FreshGuard.

Nanopath Filings

Explore SEC and related filing metadata, where available.

Nanopath filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nanopath's valuation, stock price, and market status.

Is Nanopath a public or private company?

Nanopath is a private company.

What is the current stock price of Nanopath?

Nanopath is a private company with no public stock price. No recent secondary market data is available.

How much is Nanopath worth (valuation)?

Valuation information for Nanopath is not publicly available.

Can I buy Nanopath stock?

Nanopath shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nanopath's last funding round?

Nanopath's most recent funding round was Grant on May 21, 2024.

Who are the main investors in Nanopath?

Key investors in Nanopath include SV Health Investors, Norwest Venture Partners.

Will Nanopath IPO soon?

No public IPO plans have been announced for Nanopath.

How can I track Nanopath secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nanopath's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range28
Year Founded2019
Last FundingMay 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?